|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
|
US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
|
US6090382A
(en)
*
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
HU230048B1
(hu)
|
1996-02-09 |
2015-06-29 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazása
|
|
AU710998B2
(en)
*
|
1996-03-20 |
1999-10-07 |
Bristol-Myers Squibb Company |
Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
|
|
EP1878748A2
(en)
*
|
1996-11-08 |
2008-01-16 |
Biogen Idec Inc. |
Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 costimulatory antigens
|
|
CA2292415A1
(en)
*
|
1997-06-20 |
1998-12-30 |
Innogenetics N.V. |
B7-binding molecules for treating immune diseases
|
|
IT1293795B1
(it)
*
|
1997-07-28 |
1999-03-10 |
Angelini Ricerche Spa |
Farmaco attivo nel ridurre la produzione di proteina mcp-1
|
|
ATE311199T1
(de)
|
1999-05-07 |
2005-12-15 |
Genentech Inc |
Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
|
|
AU778863B2
(en)
*
|
1999-07-12 |
2004-12-23 |
Genentech Inc. |
Blocking immune response to a foreign antigen using an antagonist which binds to CD20
|
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
|
SE9903895D0
(sv)
*
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
WO2001068133A1
(en)
*
|
2000-03-14 |
2001-09-20 |
Genetics Institute, Inc. |
Use of rapamycin and agents that inhibit b7 activity in immunomodulation
|
|
CN1981868A
(zh)
|
2000-03-31 |
2007-06-20 |
拜奥根Idec公司 |
抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
|
|
US6379900B1
(en)
|
2000-05-09 |
2002-04-30 |
Conceptual Mindworks, Inc. |
Compositions and methods of use of 8-nitroguanine
|
|
EP1294391B1
(en)
*
|
2000-06-09 |
2012-08-15 |
Bristol-Myers Squibb Company |
Combination of agents for inhibiting transplant rejection
|
|
AU6836301A
(en)
*
|
2000-06-20 |
2002-01-02 |
Idec Pharma Corp |
Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
SI1935427T1
(en)
|
2000-07-03 |
2018-05-31 |
Bristol-Myers Squibb Company |
USE OF HEATED CTLA4 MUTANT MOLECULES
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US20020058029A1
(en)
*
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
|
HUP0303930A3
(en)
*
|
2001-01-26 |
2012-09-28 |
Univ Emory |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
US6955717B2
(en)
*
|
2001-05-01 |
2005-10-18 |
Medimmune Inc. |
Crystals and structure of Synagis Fab
|
|
PL204899B1
(pl)
|
2001-05-23 |
2010-02-26 |
Bristol Myers Squibb Co |
Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
|
|
DE60230918D1
(de)
|
2001-11-16 |
2009-03-05 |
Biogen Idec Inc |
Polycistronische expression von antikörpern in cho zellen
|
|
SI1485127T1
(sl)
|
2002-02-25 |
2011-09-30 |
Elan Pharm Inc |
Dajanje aktivne snovi za zdravljenje vnetja
|
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
NZ541504A
(en)
*
|
2002-11-13 |
2009-04-30 |
Uab Research Foundation |
Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
|
|
NZ545314A
(en)
*
|
2003-08-04 |
2009-03-31 |
Bristol Myers Squibb Co |
Methods for treating cardiovascular disease using a soluble CTLA4 molecule
|
|
ATE484591T1
(de)
*
|
2003-10-21 |
2010-10-15 |
Merck Serono Sa |
Minimale dna sequenz, die als chromatin-isolator wirkt, und deren verwendung für die protein- expression
|
|
CN1902228A
(zh)
*
|
2003-11-07 |
2007-01-24 |
安姆根有限公司 |
猴免疫球蛋白序列
|
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
CN100369931C
(zh)
*
|
2005-04-07 |
2008-02-20 |
苏州大学 |
抗人b7-1分子单克隆抗体及其应用
|
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
|
EP2195331B1
(en)
|
2007-08-28 |
2013-11-20 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
EP2190469B1
(en)
|
2007-09-04 |
2015-02-25 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
EP3062106B1
(en)
|
2008-04-16 |
2020-11-11 |
The Johns Hopkins University |
Method for determining androgen receptor variants in prostate cancer
|
|
PL2483304T3
(pl)
|
2009-09-29 |
2016-11-30 |
|
Przedfiltracyjne nastawianie substancji rozpuszczonych buforu przy wytwarzaniu immu-noglobuliny o dużym stężeniu
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
EP2322149A1
(en)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of ischemia
|
|
EP2338492A1
(en)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of alzheimer
|
|
US9375473B2
(en)
|
2010-02-19 |
2016-06-28 |
Cornell Research Foundation, Inc. |
Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
NZ772688A
(en)
|
2010-06-03 |
2022-09-30 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
|
PT2580240T
(pt)
|
2010-06-14 |
2019-03-29 |
Lykera Biomed S A |
Anticorpos as100a4 e utilizações terapêuticas dos mesmos
|
|
CA2805653A1
(en)
|
2010-07-20 |
2012-01-26 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
|
WO2012061074A1
(en)
|
2010-10-25 |
2012-05-10 |
Elan Pharmaceuticals, Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
|
|
CA2817418A1
(en)
|
2010-11-10 |
2012-05-18 |
Laboratorios Del Dr. Esteve, S.A. |
Highly immunogenic hiv p24 sequences
|
|
DK2665746T3
(en)
|
2011-01-17 |
2021-02-01 |
Lykera Biomed S A |
Antibodies against the s100p protein for the treatment and diagnosis of cancer
|
|
WO2012100835A1
(en)
|
2011-01-28 |
2012-08-02 |
Laboratorios Del Dr. Esteve, S.A. |
Methods and compositions for the treatment of aids
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
CA2836373A1
(en)
|
2011-06-06 |
2012-12-13 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
|
WO2013001517A1
(en)
|
2011-06-30 |
2013-01-03 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
MX2014003689A
(es)
|
2011-09-30 |
2014-12-05 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos contra tl1a y sus usos.
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
SG2014008304A
(en)
|
2012-02-01 |
2014-06-27 |
Compugen Ltd |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
AU2013293087B2
(en)
|
2012-07-24 |
2017-08-31 |
Pharmacyclics Llc |
Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗ｍｃａｍ抗體及相關使用方法
|
|
PT2951208T
(pt)
|
2013-02-01 |
2019-12-30 |
Univ California |
Anticorpos anti-cd83 e sua utilização
|
|
KR102489953B1
(ko)
|
2013-02-07 |
2023-01-20 |
씨에스엘 리미티드 |
Il-11r 결합 단백질 및 이의 용도
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
EP2968370A4
(en)
|
2013-03-14 |
2016-09-21 |
Univ Maryland |
AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
PL2984108T3
(pl)
|
2013-04-09 |
2017-12-29 |
Lykera Biomed, S.A. |
Przeciwciała anty s100a7 do leczenia i diagnozowania nowotworu
|
|
EP3033088A4
(en)
|
2013-08-12 |
2017-03-08 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
EP2876114A1
(en)
|
2013-11-25 |
2015-05-27 |
Consejo Superior De Investigaciones Científicas |
Antibodies against CCR9 and applications thereof
|
|
RU2718054C2
(ru)
|
2013-11-28 |
2020-03-30 |
СиЭсЭл ЛИМИТЕД |
Способ лечения нефропатии
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
CN105979965B
(zh)
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
治疗伤口的方法
|
|
CA2942528A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
|
US10774387B2
(en)
|
2014-05-19 |
2020-09-15 |
The Johns Hopkins University |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
|
|
CA2954475C
(en)
|
2014-07-31 |
2023-05-16 |
Uab Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
|
AU2015300966A1
(en)
*
|
2014-08-08 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Bruton's tyrosine kinase inhibitor combinations and uses thereof
|
|
EP3186393A4
(en)
|
2014-08-25 |
2018-01-10 |
The Johns Hopkins University |
Methods and compositions related to prostate cancer therapeutics
|
|
US10870704B2
(en)
|
2014-10-23 |
2020-12-22 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
EP3233120A4
(en)
|
2014-12-19 |
2018-05-30 |
Monash University |
Il-21 antibodies
|
|
CN108368167B
(zh)
|
2015-11-27 |
2023-09-05 |
杰特有限公司 |
Cd131结合蛋白及其应用
|
|
CN105628935A
(zh)
*
|
2016-03-01 |
2016-06-01 |
广东医学院附属医院 |
一种检测人尿中cd80的试剂盒
|
|
CA3020864A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
AU2017331739A1
(en)
|
2016-09-23 |
2019-03-07 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
KR101926834B1
(ko)
|
2017-03-21 |
2018-12-07 |
동아에스티 주식회사 |
항-dr5 항체 및 그의 용도
|
|
EP3612648A1
(en)
|
2017-04-18 |
2020-02-26 |
Université Libre de Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
JP7733443B2
(ja)
|
2017-09-11 |
2025-09-03 |
モナシュ ユニバーシティー |
ヒトトロンビン受容体ｐａｒ４に対する結合タンパク質
|
|
US11466073B2
(en)
|
2017-10-18 |
2022-10-11 |
Csl Limited |
Human serum albumin variants and uses thereof
|
|
JP7390729B2
(ja)
|
2018-03-23 |
2023-12-04 |
ユニヴェルシテ リブル ドゥ ブリュッセル |
Ｗｎｔシグナル伝達アゴニスト分子
|
|
AU2019268410B2
(en)
|
2018-05-16 |
2025-01-02 |
Csl Limited |
Soluble complement receptor type 1 variants and uses thereof
|
|
TWI854983B
(zh)
|
2018-06-22 |
2024-09-11 |
日商順天生化股份有限公司 |
誘導免疫耐受之抗體、被誘導之淋巴球、及使用被誘導之淋巴球之細胞治療劑治療方法
|
|
US12234289B2
(en)
*
|
2018-12-07 |
2025-02-25 |
Ono Pharmaceutical Co., Ltd. |
Immunosuppresive agent
|
|
JP7807372B2
(ja)
|
2019-12-20 |
2026-01-27 |
ハドソン インスティチュート オブ メディカル リサーチ |
Ｃｘｃｌ１０結合タンパク質及びその使用
|
|
WO2022013613A2
(en)
|
2020-07-17 |
2022-01-20 |
Onena Medicines S.L. |
Antibodies against lefty proteins
|
|
EP4433084A1
(en)
|
2021-11-19 |
2024-09-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|
|
EP4703381A1
(en)
|
2024-09-03 |
2026-03-04 |
Institució Catalana de Recerca i Estudis Avançats |
Antibodies against icam-1 and applications thereof
|
|
WO2026068859A1
(en)
|
2024-09-30 |
2026-04-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
|